Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Simon Piggott"'
Publikováno v:
BMC Medical Education, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Telehealth is defined as the provision of health care services over a distance. Major health systems, including outpatient clinics and check-ups alike, turned to telehealth and teleconsultation amid the COVID19 pandemic. There are many recog
Externí odkaz:
https://doaj.org/article/06e1d21a1cba4ddea0b439098c1222ef
Publikováno v:
Kidney360
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bea6eb0ec02349f1a010c46eba20c0a
https://europepmc.org/articles/PMC8791362/
https://europepmc.org/articles/PMC8791362/
Publikováno v:
Clinical Case Reports: Open Access. 4
Publikováno v:
Journal of Cardiology Case Reports. 4
Autor:
Karen Thomas, Ivanka Galeva, Gerhild Angyalosi, Mark Higgins, Michael W. Konstan, Alexander Chuchalin, Simon Piggott, Florian Brockhaus
Tobramycin inhalation powder (TIP) was reported to be effective in two Phase III studies in patients with cystic fibrosis (CF) chronically infected with Pseudomonas aeruginosa (Pa). The EDIT study evaluated the efficacy and safety of TIP manufactured
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14b5b7c87c4ed30dde67410df2069fa4
Publikováno v:
Respiratory care. 59(3)
Tobramycin powder for inhalation (TIP) is a drug-device combination designed to reduce treatment time and improve ease of use compared with tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients. However, the ability of patients to use
Autor:
Thomas Siler, D Jack, Niyati Prasad, Gregory Feldman, Benjamin Kramer, Roger Owen, Mark Higgins, Simon Piggott
Publikováno v:
BMC Pulmonary Medicine
BMC Pulmonary Medicine, Vol 10, Iss 1, p 11 (2010)
BMC Pulmonary Medicine, Vol 10, Iss 1, p 11 (2010)
BackgroundIndacaterol is a novel, once-daily (o.d.) inhaled, long-actingβ2-agonist in development for chronic obstructive pulmonary disease (COPD). This 12-week, double-blind study compared the efficacy, safety, and tolerability of indacaterol to th
Autor:
Damon Jack, Mark Higgins, David Ramos-Barbon, Benjamin Kramer, Simon Piggott, Claus Vogelmeier, Roger Owen
Publikováno v:
Chest. 136:4S
Autor:
Simon Piggott, Roger Owen, D Jack, Mark Higgins, Claus Vogelmeier, Benjamin Kramer, David Ramos-Barbón
Publikováno v:
Respiratory Research
Respiratory Research, Vol 11, Iss 1, p 135 (2010)
Respiratory Research, Vol 11, Iss 1, p 135 (2010)
Background Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β2-agonist for the treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind study compared the bronchodilator efficacy of indacaterol with that